



## PRESS RELEASE

# Perspixon Biotech attended a panel discussion at the 10th German-Chinese Economics Conference in Darmstadt, Germany

**Frankfurt, November 2023**

On 6th November 2023, Perspixon Biotech attended the 10th German-Chinese Economics Conference in Darmstadt. The conference was organized by Rudolf Scharping from RBSK AG.

<https://bri-rsbk.de/de/programm.html?c=accept>

Matthias Wiedenfels took stage during a panel discussion focused on "Flashlights Innovations & Start-Ups". The conference comprised a series of panels and presentations from leading Germany and Chinese companies and Startups, accompanied by expert outlooks on investment and partnering activities in both countries.

Perspixon used this opportunity to connect with Chinese investors and industry partners.

\*\*\*

**For further media information/interview opportunities please contact:**

Dr. José Airas

T +49 (0)177 577 9828

E [info@perspixonbio.tech](mailto:info@perspixonbio.tech)

### Notes to editors:

*Perspixon is a biotech company specialized in multi-specific antibodies. Perspixon creates next-generation biotherapeutics through an end-to-end automated discovery platform. The company aims to radically accelerate the technical development of biological drug modalities with predictive AI, significantly reducing drug development times and costs. The roPROTix platform automatically generates tens of thousands of in-silico designed modalities and analyses them for key functional and biophysical properties in a parallelized approach. This digitally integrated process generates interrelated and multidimensional datasets of unprecedented quantity and quality, which feed directly into ML algorithms that drive the in-silico design engine.*

*Perspixon is headquartered in the FIZ Frankfurt Innovation Center for Biotechnology, Germany*